Drugs / Mepivacaine
Mepivacaine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CARBOCAINE | — | 1960-01-06 | fda.gov ↗ |
Trials 27 · a red edge is where a trial was stopped
195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06005480 | Sep 2023 → May 2024 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04113954 | Sep 2020 → Apr 2021 | compartment syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01032798 | May 2007 → May 2008 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07672301 | Mar 2026 → Jun 2027 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05222828 | Jun 2022 → Jun 2024 | ischemic stroke | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT04947267 | May 2018 → Sep 2019 | — | Afshan Amjad Ali | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03725579 | Sep → Dec 2018 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06271174 | Jun 2024 → Jun 2026 | — | Nantes University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02078063 | Nov 2013 → Nov 2017 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT01522534 | Jan 2012 → Dec 2013 | — | Centre Hospitalier Annecy Genevois | Terminated | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT04454203 | Feb 2021 → Feb 2027 expected | — | Duke University | Recruiting | No outcome recorded |
| Phase 4 | NCT05252117 | Feb 2021 → Apr 2022 | — | Universidade do Vale do Sapucai | Unknown | No outcome recorded |
| Phase 4 | NCT03390426 | May → Oct 2018 | — | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT03138577 | Feb 2018 → Jul 2019 | — | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT03368391 | Jan → Jun 2018 | dental pulp disorder, local anesthetic poisoning | Louisiana State University Health Sciences Center in New Orleans | Unknown | No outcome recorded |
| Phase 4 | NCT02980926 | Dec 2016 → Mar 2017 | osteoarthritis, knee | Henry Ford Health System | Completed | No outcome recorded |
| Phase 4 | NCT02909049 | Apr 2016 → Jan 2018 | prostate cancer | Complexo Hospitalario Universitario de A Coruña | Completed | No outcome recorded |
| Phase 4 | NCT01574807 | May 2012 → May 2013 | — | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT02054767 | Aug 2010 → Nov 2012 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06092541 | Oct 2023 → May 2024 | — | Ospedale degli Infermi di Biella | Completed | No outcome recorded |
| — | NCT05728151 | Feb 2022 → Apr 2024 | strabismus | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| — | NCT03745105 | Dec 2018 → Dec 2019 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT05239078 | Mar 2016 → Feb 2017 | pulpitis | Dr. Vivek Aggarwal | Completed | No outcome recorded |
| — | NCT04822415 | Dec 2014 → Dec 2016 | pulpitis | Cairo University | Completed | No outcome recorded |
| — | NCT01701115 | Aug 2012 → Aug 2013 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| — | NCT01485653 | Apr → Aug 2010 | peripheral nerve lesion | Wayne State University | Completed | No outcome recorded |
| — | NCT00803725 | Aug 2008 → May 2009 | — | University Health Network, Toronto | Completed | No outcome recorded |
Also used as a comparator or background therapy in 48 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05445921 Background | Sep → Dec 2022 | anosmia, olfactory nerve disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01860417 Comparator | Jun 2013 → Dec 2015 | intervertebral disk degenerative disorder | Red de Terapia Celular | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06253806 Comparator | Oct 2023 → Sep 2024 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03365752 Comparator | Jun 2018 → Feb 2021 | — | Hospital for Special Surgery, New York | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03838874 Comparator | Feb → Oct 2019 | osteoarthritis, hip, osteoarthritis, knee | Mayo Clinic | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05839548 Comparator | Jul 2023 → May 2025 overdue | dental caries, dental pulp disorder | Qassim Health Cluster | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05444751 Background | Mar 2022 → Sep 2026 expected | lumbar disk disease, radiculopathy | Hospital for Special Surgery, New York | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT04477317 Comparator | Aug → Sep 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT00825786 Comparator | Sep 2008 → Aug 2010 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 421 trials | ||||||
| Phase 4 | NCT07239999 Comparator | Mar 2026 → Apr 2027 expected | — | Nova Scotia Health Authority | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07601750 Comparator | Jan 2025 → Dec 2028 expected | — | Baylor Research Institute | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05425979 Comparator | Mar 2024 → Dec 2026 expected | ankle defects short stature | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06291727 Comparator | Feb 2024 → Aug 2025 | osteoarthritis, knee | Prisma Health-Upstate | Completed | No outcome recorded |
| Phase 4 | NCT07013071 Comparator | Feb → May 2024 | — | King Abdulaziz University | Completed | No outcome recorded |
| Phase 4 | NCT05980546 Background | Jun 2023 → Sep 2025 | substance-related disorder | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT04257682 Comparator | Sep 2022 → Feb 2023 | osteoarthritis, hip, osteoarthritis, knee | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT03948386 Comparator | May → Nov 2019 | osteoarthritis, hip | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT03378323 Comparator | Jul 2018 → Apr 2019 | — | Valais Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03264586 Comparator | Aug 2017 → Mar 2018 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03063255 Comparator | Apr 2017 → Sep 2019 | urinary bladder cancer | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT03470532 Comparator | Feb 2017 → Mar 2018 | — | Melaka Manipal Medical College | Completed | No outcome recorded |
| Phase 4 | NCT03046108 Comparator | Jan 2016 → Aug 2018 | Morton neuroma | Complejo Hospitalario Universitario de Granada | Unknown | No outcome recorded |
| Phase 4 | NCT02384915 Comparator | Jan → May 2015 | osteoarthritis, knee | ASST Gaetano Pini-CTO | Completed | No outcome recorded |
| Phase 4 | NCT02162121 Background | May 2014 → Oct 2016 | — | ASST Gaetano Pini-CTO | Completed | No outcome recorded |
| Phase 4 | NCT02110966 Comparator | Apr → Oct 2014 | pulpitis | Daniel Chavarría Bolaños | Completed | No outcome recorded |
| Phase 4 | NCT01981291 Background | Oct 2012 → Jul 2013 | — | University of Parma | Completed | No outcome recorded |
| Phase 4 | NCT01611324 Background | May → Dec 2012 | varicose disease | Campus-Bio-Medico University | Completed | No outcome recorded |
| Phase 4 | NCT02433899 Background | Oct 2010 → Apr 2012 | gingival recession | Fluminense Federal University | Completed | No outcome recorded |
| Phase 4 | NCT01719978 Comparator | Oct 2007 | cardiac rhythm disease | Mauricio Jose Tornelli | Completed | No outcome recorded |
| Phase 4 | NCT00567450 Comparator | Sep 2007 → Sep 2008 | — | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT07298746 Comparator | Dec 2025 → Dec 2026 expected | — | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT06927726 Comparator | Jan → Feb 2025 overdue | hypertensive disorder | Tanta University | Enrolling by invitation | No outcome recorded |
| — | NCT06172400 Background | Jan → Dec 2024 | carpal tunnel syndrome | Region Skane | Unknown | No outcome recorded |
| — | NCT06155903 Comparator | Dec 2023 → Apr 2024 | — | Federico II University | Completed | No outcome recorded |
| — | NCT07246434 Background | Sep 2023 → Apr 2024 | rotator cuff syndrome | Universidad de Extremadura | Completed | No outcome recorded |
| — | NCT05875519 Background | May → Nov 2023 | diabetes mellitus | Minia University | Completed | No outcome recorded |
| — | NCT06128590 Background | Feb 2023 → Feb 2024 | — | University of Nove de Julho | Completed | No outcome recorded |
| — | NCT05338983 Background | May 2022 → May 2023 | — | Mansoura University | Unknown | No outcome recorded |
| — | NCT05238727 Comparator | Mar 2022 → Mar 2023 | pulpitis | Cairo University | Unknown | No outcome recorded |
| — | NCT05136625 Background | Feb 2021 → Jan 2024 | — | University Hospital of Ferrara | Unknown | No outcome recorded |
| — | NCT04561921 Comparator | Oct 2020 → Oct 2021 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT03942991 Comparator | Sep → Nov 2019 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04509440 Comparator | May 2018 → Oct 2019 | pes anserinus tendinitis or bursitis | University of Alexandria | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02584452 Comparator | Nov 2015 → Mar 2018 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT03211949 Background | Sep 2014 → Dec 2019 | brachial plexus neuropathy, peripheral nerve lesion | University Hospital, Antwerp | Completed | No outcome recorded |
| — | NCT02603198 Comparator | Aug 2014 → Jun 2015 | — | University of Sao Paulo | Unknown | No outcome recorded |
| — | NCT01533545 Comparator | Sep 2012 → Sep 2014 | chronic kidney disease | Rigshospitalet, Denmark | Terminated | No outcome recorded |
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 77 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mepivacaíne | “A patient, suffering from cortical blindness after a bi-occipital infarction 1 year earlier, regained near-normal vision in the right visual hemifield a few minutes after...” NCT05222828 ↗71“Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.” NCT06155903 ↗ “All patients will receive the same type and amount of local anesthetic: 30 ml of a mixture of ropivacaine 0.5 % + mepivacaine 1 %.” NCT03378323 ↗ “injections of 3.6 mL of 2% mepivacaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection” NCT02054767 ↗ “For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used.” NCT05444751 ↗ “Local anesthesia with 5 mL mepivacaine 2% is applied subacromially prior to PRP administration.” NCT07246434 ↗ “after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.” NCT05445921 ↗ “Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine)” NCT05136625 ↗ “The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.” NCT03138577 ↗ “either Group M (3.6 ml Mepivacaine hydrochloride 2% with 1:100000 epinephrine)” NCT03725579 ↗ “6-8 mL of 1% mepivacaine will be injected near the stellate ganglion.” NCT06253806 ↗ “An inferior alveolar nerve block was given with 3% plain mepivacaine” NCT05239078 ↗ “Mepivacaine/Lidocaine 1.5% 10/15 ml (max dose 7 mg/kg) will be used” NCT06092541 ↗ “Spinal-block (mepivacaine 2%, 3.0 mL)” NCT07672301 ↗ “Mepivacaíne 3%” NCT05252117 ↗ “Mepivacaine” NCT03063255 ↗ |
| Known as | 1-methyl-2',6'-pipecoloxylidide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | 2',6'-pipecoloxylidide, 1-methyl- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | APF-135 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Arestocaine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Carbocain | “10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter” NCT02078063 ↗ |
| Known as | Carbocaïne | “Carbocaïne will be injected around the nerve responsible of the innervation of the operated area by echography guidance.” NCT06271174 ↗ |
| Known as | Carboplyin dental | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | chloridrato mepivacaine | “In the MEPI-LEVO group, the patient will receive local anesthesia employing 2% chloridrato mepivacaine with 1:20.000 levonordefrin at a maximum of four cartridges of anesthesia.” NCT02603198 ↗ |
| Known as | Dl-mepivacaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Isocaine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Mepisv | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Mepivacaina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | MEPIVACAINE 2% ATC N01BB03 MAN 62606 | “MEPIVACAINE 2% ATC N01BB03 MAN 62606” NCT02909049 ↗ |
| Known as | Mepivacaine HCL | “Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic.” NCT05338983 ↗4“1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl” NCT04561921 ↗ “Drug: Mepivacaine HCL” NCT03745105 ↗ |
| Known as | Mepivacaine hydrochloride | “Participants in this group received local anesthesia consisting of 2% mepivacaine hydrochloride with 1:100,000 (0.01 mg/mL) epinephrine prior to simple mandibular tooth extraction.” NCT07013071 ↗6“either Group M (3.6 ml Mepivacaine hydrochloride 2% with 1:100000 epinephrine)” NCT03725579 ↗ “Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge” NCT03470532 ↗ “1.8 ml mepivacaine hydrochloride” NCT05238727 ↗ “Drug: Mepivacaine Hydrochloride” NCT07601750 ↗ “3% Mepivacaine Hydrochloride” NCT04947267 ↗ |
| Known as | Mepivacaine is also known as Carbocaine | “Mepivacaine is also known as Carbocaine” NCT01860417 ↗ |
| Known as | Mepivacaine is also known as Polocaine | “Mepivacaine is also known as Polocaine” NCT01860417 ↗ |
| Known as | Mepivacaine monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Mepivacaine Normon 2% | “blind injection of 1 cc of Mepivacaine Normon 2% ®” NCT03046108 ↗ |
| Known as | NSC-758674 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Optocain | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Polocaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Polocaine-mpf | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Scandicain | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Scandicaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03211949 ↗ |
| Known as | Scandonest | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Scandonest plain | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Known as | Tevacaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1087 ↗ |
| Modality | Other / unclassified | “local anesthetics” NCT00567450 ↗ |
| Route | Intrathecal | “30 mg of isobaric mepivacaine 1.5% plus fentanyl 10 microg (M + F group) or 45 mg of isobaric mepivacaine 1.5% alone (M group) intrathecally” PMID 19856040 ↗ Oct 2009 |